Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab-based alternating chemotherapy for newly diagnosed B-precursor acute lymphoblastic leukaemia
ACTRN12617000084381Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- May 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of blinatumomab, methotrexate and cytarabine in acute lymphoblastic leukemia (ALL), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Event-free status. Started May 2018; status: completed.
02
Drugs
blinatumomabmethotrexatecytarabine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ACTRN12617000084381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000084381.